Modern Retina

As the 2024 ASRS meeting draws nearer, more companies announce the presentations related to their research. The annual event will take place in Stockholm, Sweden, July 17-20, 2024. Read more: https://lnkd.in/eXQ44Qwa

A review shows sozinibercept’s potential to prevent blood vessel growth and vascular leakage in the retina as a treatment for wet AMD. The recognition is that the “pathophysiology is broader than dysregulation or overproduction of VEGF-A. Read more: https://lnkd.in/ePDJWUcB

Boston researchers reported that there is a potential risk of the development of non-arteritic ischemic optic neuropathy (NAION) associated with prescriptions for semaglutide (Wegovy, Ozempic, Novo Nordisk). Read more: https://lnkd.in/eV5jS_uV

A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred central vision in wet AMD. Read more: https://lnkd.in/eDRXzQBg

Genentech, a member of the Roche group, has received FDA approval to relaunch Susvimo (ranibizumab injection 100 mg/mL) for intravitreal use via an ocular implant for treating people with wet (or neovascular) age-related macular degeneration (AMD). Read more: https://lnkd.in/eHVbvwD4

The 42nd annual meeting of the American Society of Retina Specialists (ASRS) is slated to convene in the northern European capital city of Stockholm from July 17-20, 2024. The venue is the Stockholmsmässan Convention Center, Stockholm. Read more: https://lnkd.in/eBhswn5i

Genentech this week announced the FDA has approved faricimab-svoa (Vabysmo) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Read more: https://lnkd.in/euFJ2war

The European Medicines Agency (EMA) issued a new opinion from its Committee for Medicinal Products for Human Use (CHMP), regarding faricimab (Vabysmo). Read more: https://lnkd.in/ex423XWc

Altos Biologics Inc. has submitted the Marketing Authorization Application to the European Medicines Agency (EMA) for ALT-L9, an aflibercept biosimilar. This biosimilar was developed by Alteogen. Altos Biologics Inc. is a subsidiary of Alteogen. Read more: https://lnkd.in/eXtTM_uj

During interview earlier this year, we asked leaders in the retina field would tell residents and medical students as they train for the next decades in retinal care. Here's what Durga Borkar, MD, MMCi, and Jaclyn L. Kovach, MD, had to say. Watch now: https://lnkd.in/euSpfrGu